Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1Neuroblastoma 1Multiple Endocrine Neoplasia 1Carcinoma, Neuroendocrine 1Carcinoid Tumor 1Adrenal Gland Neoplasms 1

Interventions

Adrenalectomy 5Radiosurgery 2Nivolumab 2Magnetic Resonance Spectroscopy 2Fluorodeoxyglucose F18 2FAPI-46 2pertuzumab 1olaparib 1lutetium Lu 177 dotatate 1iodophenyl metomidate 1camrelizumab 1apatinib 1X-Rays 1Surgical Procedures, Operative 1Radiofrequency Ablation 1Quality of Life 1Patient Reported Outcome Measures 1Observation 1Nephrectomy 1N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride 1Molecular Diagnostic Techniques 1Mitotane 1Immunotherapy 1Gefitinib 1Floxuridine 1Erlotinib Hydrochloride 1Endosonography 1Endoscopic Ultrasound-Guided Fine Needle Aspiration 1Drug Therapy 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenal Gland Neoplasms × pertuzumab × Endocrine × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡